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surgery and 5 years of adjuvant tamoxifen to postoperative 
whole breast irradiation or no further therapy. At a median 
follow up of 5.7 years the local recurrence rate was reduced 
by RT from 4% to 1%. However there has been limited impact 
on practice.  A survey of Medicare patients (2) who met the 
eligibility criteria of the CALGB 9943 trial showed 
approximately a 3% reduction in use of adjuvant radiotherapy 
in a period following the publication of the 5 year results of 
the CALBG trial. The reasons for this limited impact on 
practice are uncertain.The 10 year results of the CALGB 9943 
(3) show that the difference in local control has widened(2% 
vs 9%). In the UK postoperative radiotherapy remains the 
standard of care for all patients technically suitable for 
radiotherapy irrespective of age and other clinico-
pathological risk factors. The benefits of adjuvant 
radiotherapy on local control have to be balanced against the 
issues of comorbidity, breast toxicity, risks of second 
malignancy(4) and the costs of radiotherapy. Results will be 
presented from the international PRIME 2 trial in over 1300 
hormone receptor positive, T1-2 (up to 3cm) pNO  breast 
cancer in women =/> 65 years treated by breast conserving 
surgery and adjuvant endocrine therapy with or without 
postoperative radiotherapy (5). A case can be made for 
offering selected older patients the option of the omission of 
RT. Techniques of partial breast irradiation are also being 
investigated which might be more convenient and less morbid 
than whole breast irradiation. 
There is limited level 1 evidence on the impact on quality of 
life of adjuvant radiotherapy. The PRIME quality of life trial 
suggests that there is no significant difference in global 
quality of life in early breast cancer patients treated by 
breast conserving surgery with or without whole breast 
irradiation(6). 
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Hypofractionation has lately been implemented as standard 
treatment in the adjuvant setting as well as in radical 
radiotherapy for various solid tumors such as in breast and 
lung carcinomas. Also for metastatic disease in the liver or 
brain, hypofractionated stereotactic radiotherapy has proven 
effective for both palliative purposes and sometimes cure. 
Palliative schedules have conventionally been designed to 
deliver sufficient radiation dose within a short period of time 
to achieve optimal palliation with particular consideration to 
life expectancy. Such treatment strategies may be assigned 
to frail and elderly patients at the expense of curative 
fractionation schedules, particularly for logistic reasons in 
those with impaired functional conditions, that the patient 
may better comply to treatment. However, data from 
DAHANCA showed no impact of age, comorbidity, or WHO 
performance status on delay of treatment in patients 
undergoing a fast-track work-up for head and neck cancer 
(H&N), and elderly patients (above 70) demonstrated 
equivalent compliance to prescribed radical radiation 
treatment compared to younger patients which was further 
translated into similar cancer-specific survival figures 
between the age-groups. However, if for a particular clinical 
reason a reduced treatment time is opted for in an the 
elderly H&N patient, several considerations should  be made. 
Whether the intention of treatment is palliative or curative, 
treatment volume and fractionation schedules are obviously 
related to toxicity. Elderly H&N patients with a low 
propensity for HPV-derived carcinomas have generally lower 
rates of neck metastases than younger patients (N0-1 below 
20% vs 35%) which defines a smaller target area. With modern 
diagnostic procedures and cone-beam based adaptive IMRT 
techniques, both dose-planning and execution of radiation 
treatment have become more precise which elderly patients 
may profit from, particularly if elective radiation is omitted, 
similar to stereotactic strategies. Delivery of 30 Gy in 10 
fraction over 2 weeks, or 20 Gy in 5 fx, confer a dose-
intensity much higher than conventional or accelerated 
regimens and, consequently, increases the risk of severe 
mucositis. We have adopted a hypofractionated schedule 
from the DAHANCA 2 trial consisting of 52 Gy in 13 fractions 
with two weekly fractions (8 Gy per week). This has secured 
a tolerable treatment schedule with a considerably high 
radiobiological dose for potential cure. Toxicity has been 
mild in comparison to standard fractionation, and the 
schedule has been employed for patients considered 
unsuitable for standard treatment. IMRT and VMAT are easily 
applied in hypofractionated regimens for elderly patients 
since these techniques have become standard of care, and 
acceptable toxicity and cure rates are expected. 
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Rapid population ageing in most area of the developed world 
substantially contributes to the significant increase in the 
cancer burden in the elderly. In the subgroup of cancer 
patients’ (pts) over-75 years of age, for ex, prostate cancer 
(PCa) becomes the most common tumour diagnosed in men in 
Europe and North America. On the other hand, life 
expectancy is increasing in western countries and this 
translates in a general feeling that curative treatment 
options should be offered even to elderly pts independently 
of their chronological age. Oncologists treating a geriatric 
population of pts face several major issues when developing 
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therapeutic strategies addressed to these pts. At first it has 
become evident that any age-cut-off adopted to identify 
“elderly pts” ( > 65 yo, > 75 yo or even > 85 yo) has intrinsic 
limitations because geriatric pts are an extremely 
heterogeneous group with respect to their general health 
status. Second, a comprehensive geriatric assessment is 
needed to stratify and weigh the spectrum of 
dysfunctions present at old ages in order to select pts 
suitable for treatment (with standard protocol or with 
adapted ones). Several instruments and screening tools are 
proposed in the literature aiming at evaluate the 
vulnerability of elderly cancer pts: from complex and time 
consuming procedures to more easy to apply ones and to self-
administered questionnaires based on self-assessment of a 
short list of items. Finally elderly pts should be evaluated 
during and after their cancer treatments in order to detect 
signs and symptoms related to potential complications due to 
the treatment itself in order to eventually modulate it 
accordingly. 
Brachytherapy (BT) is an attractive treatment option for 
elderly cancer patients and this is especially true for prostate 
and gynaecological malignancies. The International Society of 
Geriatric Oncology (SIOG) Radiotherapy Task Force has 
reviewed the current best practice and priorities for research 
in radiation oncology for elderly patients with cancer. It has 
been stated that life expectancy and comorbidities should 
influence the selection criteria for prostate BT and that an 
international consensus is needed to define the subset of 
geriatric pts for prospective evaluation of BT acknowledging 
that a specific literature on BT for this group of cancer pts is 
virtually non-existent. Interestingly enough the same paper 
addresses the issue of BT (vaginal Brachytherapy, VBT) for 
postoperative irradiation of pts diagnosed with Endometrial 
cancer (ECa) in the Intermediate to High Risk Group. The 
PORTEC-2 Trial has found no significant differences between 
external beam RT and VBT in pts > 60 years old in terms of 
local or distant recurrence rates, but with a reduced toxicity 
and improved quality of life making VBT the adjuvant 
treatment option in this setting. Furthermore, the last up-
date of the Guidelines of the European Association of Urology 
(EAU) devotes a specific chapter to the Management of 
Prostate Cancer in Older Men, recognizing that this is 
a specific subgroup of PCa pts emphasizing that, according to 
published results from the US Surveillance Epidemiology and 
End Results (SEER) database, 71 % of PCa-related deaths 
occur in men aged ≥ 75 years. Surprisingly enough, after a list 
of rather generic recommendations about the need of a 
comprehensive baseline evaluation of life expectancy, 
comorbidities and health status, BT is not even mentioned in 
the paragraph devoted to the treatment of localized 
disease…On the contrary, the recently published Updated 
recommendations of the working party on the management 
of PCa of the SIOG, clearly states that BT “can be a suitable 
option for older men with PCa”, but any further details is 
given concerning the profile of the “suitable” pts. 
In conclusion, the general picture of the management of 
older pts with PCa or gynaecological malignancies is rapidly 
changing: particular attention is nowadays reserved to this 
subset of pts. Specific and details guidelines are still lacking 
but the oncological community is aware of the importance of 
a tailored approach that has to take into account a correct 
evaluation of the baseline profile of the pt before any 
treatment can be proposed.    
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Experimental microdosimetry is performed with TEPC (Tissue 
Equivalent Proportional Counter) that are able to measure 
the stochastic of radiation interaction with micrometric 
sensitive volumes. To measure ionizations produced in 
microscopic site with a macroscopic volume, TEPC are filled 
with low-pressure gas. At Legnaro National Laboratories of 
INFN new TEPC have been developed that are able to 
measure high intensity therapeutic beams. They are called 
mini-TEPC because of their small dimensions of the sensitive 
volume. Moreover, miniaturization involves also the external 
dimensions since the counter is inserted in a titanium sleeve 
of 2.7mm external diameter. Mini-TEPCs have been tested 
under different fields. With proton beams, they showed that 
is possible to assess the RBE of proton beam by using a proper 
weighting function.  
It is possible to perform microdosimetry at nanometric level, 
at least down to 25nm, with an avalanche confinement TEPC. 
An Italian research project called MITRA is developing this 
kind of detector for ion beams.  
Finally, in the world there are only three operative 
nanodosimeters. They measure the track structure of the 
beam: two of them are able to measure the track structure 
due to the beam core and the penumbra. The BioQuaRT 
project compared the responses of the three nanodosimeters. 
The three nanodosimeters are very different as well as their 
outputs in terms of ICSD (Ionization Cluster Size 
Distributions). However, the sum distribution Fk versus M1 of 
the three devices forms an almost perfect universal curve, 
and shows a saturation effect like radio-biological cross 
sections as a function of LET. 
Results will be presented.  
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Monte Carlo simulations are commonly used in radiobiology or 
medical applications for evaluating the energy deposition of 
ionizing radiation in biological targets. Nevertheless, trying 
to predict the earlier radio-induced biological effects in a 
cell population starting from an accurate description of the 
energy deposition at their origin needs the development of 
dedicated simulation tools. The first requirement of these 
simulation tools is their capability to calculate the track 
structure of the ionizing radiation with nanometric precision. 
Indeed, the nanometer scale corresponds to molecular 
dimensions and in particular to the scale of the DNA molecule 
that is the main target for which radiation damages can be 
linked to mutagenic or even lethal effects. Several dedicated 
simulation tools for this purpose have been developed in the 
last decades, following a mechanistic approach for the 
simulation of early radiation-induced biological effects. In 
